Publications by authors named "Tsujimoto S"

Primary intracranial sarcoma (PIS) is a rare and aggressive pediatric brain tumor, which is partially associated with DICER1 mutant. Although the molecular genetic characteristics of this tumor have previously been investigated, novel therapeutic targets remain unclear. Further, the lack of faithful preclinical models has hampered the development of novel therapeutic strategies.

View Article and Find Full Text PDF

We prepared biocompatible elastic fibers with high porosity and high tensile strength from poly[()-3-hydroxybutyrate--4-hydroxybutyrate], which is a microbial polyester that can be produced from renewable carbon resources by isothermal crystallization. It was possible to control the pore size by adjusting the isothermal crystallization time. Most of the pores were approximately less than 10 μm in diameter, did not penetrate, and were distributed discontinuously throughout the fibers.

View Article and Find Full Text PDF

Animals likely use a variety of strategies to solve laboratory tasks. Traditionally, combined analysis of behavioral and neural recording data across subjects employing different strategies may obscure important signals and give confusing results. Hence, it is essential to develop techniques that can infer strategy at the single-subject level.

View Article and Find Full Text PDF

Objective: The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and efficacy (as an exploratory endpoint) of TCK-276, a novel CDK4/6 inhibitor, after multiple oral doses for 7 days in patients with active RA.

Methods: This multicentre, randomized, placebo-controlled, dose-ascending, double-blind, phase 1b, multiple-dose study included 32 patients with active RA in 4 cohorts of 8 patients (6 active and 2 matching placebo), each receiving an oral dose of TCK-276 or matching placebo for 7 days (once daily). The doses of TCK-276 were 10, 25, 75, and 175 mg/day.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explores the molecular pathology of acute myeloid leukemia (AML), focusing on the discovery of important genetic markers for risk assessment and the need for new treatment approaches, especially for patients with relapsed or refractory AML.
  • - Researchers conducted ATAC-seq analysis on 10 AML patients, finding increased accessibility of the DOCK1 gene, which subsequently led to further testing on 369 pediatric AML patients to evaluate DOCK1 gene expression levels.
  • - Results showed that high DOCK1 expression (noted in 37% of patients) correlated with significantly poorer overall and event-free survival rates; experiments suggest that using a DOCK1 inhibitor may enhance the efficacy of cytarabine, a common AML treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Innovations in sequencing technology have improved the detection of genetic mutations related to inherited diseases, yet many patients remain undiagnosed due to limitations in current methods.
  • The study introduces a new computational workflow for target adaptive sampling long-read sequencing (TAS-LRS) that enhances diagnostic accuracy by effectively identifying both single nucleotide variants and complex structural variations.
  • The TAS-LRS method not only discovered new mutations related to familial adenomatous polyposis and Lynch syndrome but also demonstrated the potential to analyze off-target reads for comprehensive genetic risk assessments.
View Article and Find Full Text PDF

Myxoid pleomorphic liposarcoma (MPLS) is an extremely rare tumor listed in the fifth edition of the WHO classification (2020). Histologically, it mainly comprises a mixture of myxoid and pleomorphic liposarcoma-like components. Genetically, it lacks fusion and amplification.

View Article and Find Full Text PDF

The O splitting mediated by the bulky Rind-based diphosphenes resulted in the clean formation of the mixed-valent diphosphorus compounds, diphosphene oxides, with PO moieties. Their structural features and electronic properties have been clearly characterized by experimental and theoretical methods.

View Article and Find Full Text PDF

Here, we report the marine degradability of polymers with highly ordered structures in natural environmental water using microbial degradation and biochemical oxygen demand (BOD) tests. Three types of elastic fibers (non-porous as-spun, non-porous drawn, and porous drawn) with different highly ordered structures were prepared using poly[()-3-hydroxybutyrate--16 mol%-4-hydroxybutyrate] [P(3HB--16 mol%-4HB)], a well-known polyhydroxyalkanoate. Scanning electron microscopy (SEM) images indicated that microorganisms attached to the fiber surface within several days of testing and degraded the fiber without causing physical disintegration.

View Article and Find Full Text PDF

The tumor microenvironment (TME) is thought to influence the antitumor efficacy of immuno-oncology agents through various products of both tumor and stromal cells. One immune-suppressive factor is prostaglandin E (PGE), a lipid mediator whose biosynthesis is regulated by ubiquitously expressed cyclooxygenase- (COX-) 1 and inducible COX-2. By activating its receptors, PGE induces immune suppression to modulate differentiation of myeloid cells into myeloid-derived suppressor cells (MDSCs) rather than dendritic cells (DCs).

View Article and Find Full Text PDF

CD25 is an aberrant marker expressed on the leukemic stem cell (LSC) surface and an immunotherapy target in acute myeloid leukemia (AML). However, the clinical prevalence and significance of CD25 expression in pediatric AML are unknown. High IL2RA/CD25 expression in pediatric AML showed a stem cell-like phenotype, and elevated CD25 expression was associated with lower overall survival (p < .

View Article and Find Full Text PDF

Autoimmune lymphoproliferative syndrome (ALPS) is a disease of lymphocyte homeostasis caused by FAS-mediated apoptotic pathway dysfunction and is characterized by non-malignant lymphoproliferation with an increased number of TCRαβ+CD4-CD8- double-negative T cells (αβDNTs). Conversely, RAS-associated leukoproliferative disease (RALD), which is caused by gain-of-functional somatic variants in KRAS or NRAS, is considered a group of diseases with a similar course. Herein, we present a 7-year-old Japanese female of RALD harboring NRAS variant that aggressively progressed to juvenile myelomonocytic leukemia (JMML) with increased αβDNTs.

View Article and Find Full Text PDF
Article Synopsis
  • Acute Myeloid Leukemia (AML) is the second most common leukemia in children, and recent genomic advances show its mutational differences compared to adult AML.
  • Survival rates for children with AML have improved significantly over the past 40 years, now reaching 70-80% in developed countries due to better chemotherapy, risk assessment, and stem cell treatments.
  • Despite progress, the main treatment methods for pediatric AML have remained largely unchanged, highlighting the need for better risk stratification and new therapies through global collaboration to enhance outcomes further.
View Article and Find Full Text PDF

The trematode Postharmostomum commutatum is a parasite of the chicken Gallus gallus domesticus. Its heavy infection can cause inflammation and hemorrhage in the cecum of host birds. We found a severe infection of metacercariae of P.

View Article and Find Full Text PDF
Article Synopsis
  • Second malignant neoplasms (SMNs) are serious complications that can develop after pediatric cancer treatment, and this study investigates the genetic factors that may influence their occurrence.
  • The researchers conducted whole-exome sequencing on 14 pediatric patients with SMNs and found that 35.7% had harmful genetic mutations in cancer-predisposing genes, particularly in TP53 and DICER1, which is significantly higher than in a control group.
  • The findings suggest that genetic variations, along with treatments like platinum drugs, contribute to the risk of developing secondary cancers, indicating the need for thorough genetic analysis to better predict and manage these risks in pediatric cancer survivors.
View Article and Find Full Text PDF

Background: Data regarding the incidence, predictive factors, and clinical outcomes of post-transcatheter aortic valve replacement (TAVR) bleeding is limited in the Asian cohort.

Objectives: This study sought to assess the predictors and prognostic impact of post-TAVR late bleeding.

Methods: This study used the Japanese multicenter registry data to analyze 2,518 patients (mean age: 84.

View Article and Find Full Text PDF

Frailty is strongly associated with poor short- and long-term prognoses in patients who undergo transcatheter aortic valve implantation (TAVI). However, limited data are available regarding the association between frailty and late bleeding events after TAVI. Of the 2,518 patients in the Japanese multicenter TAVI registry, 1371 patients with complete data on frailty parameters were analyzed.

View Article and Find Full Text PDF

Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody-positive dermatomyositis is a disease with a poor prognosis associated with rapid progressive interstitial pneumonia. Autoimmune diseases have occasionally been reported to occur after hematopoietic stem cell transplantation (HSCT). We experienced a case of anti-MDA-5 antibody-positive dermatomyositis after HSCT.

View Article and Find Full Text PDF
Article Synopsis
  • 6-Mercaptopurine (6-MP) is used to treat pediatric leukemia and lymphoma, but genetic variations in the NUDT15 gene can lead to severe side effects like myelosuppression.* -
  • Patients with certain NUDT15 variants have higher levels of a toxic compound in their blood, which is linked to increased risk of myelosuppression during treatment with 6-MP.* -
  • A study found that lower NUDT15 protein levels are strongly associated with adverse effects of 6-MP, highlighting the importance of genetic testing for tailored treatment strategies.*
View Article and Find Full Text PDF
Article Synopsis
  • The study aims to determine the right treatment intensity for children under 16 diagnosed with de novo acute myeloid leukemia, focusing on those with specific genetic markers and minimal residual disease after initial treatment.
  • It specifically evaluates the safety and effectiveness of combining gemtuzumab ozogamicin (GO) with post-induction chemotherapy for patients identified as non-low-risk (intermediate-risk and high-risk).
  • The main goal is to measure the three-year disease-free survival rate between groups receiving GO versus those not receiving it, while high-risk patients will undergo stem cell transplantation in their first remission.
View Article and Find Full Text PDF